Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.
Journal Information
Full Title: BMC Urol
Abbreviation: BMC Urol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Ethics approval and consent to participateThis study was conducted in accordance with International Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Shiraz University of Medical Sciences, code IR.SUMS.NUMIMG.REC.1401.051. also considering that this study did not contain patients, there was no need to obtain consent. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding None."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025